Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
| Brand name | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE |
| Generic name | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE |
| Active ingredient(s) | HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM |
| Distributed by / for | Macleods Pharma Usa Inc |
| NDC | 33342-052-07 |
| Full product label | Losartan Potassium & Hydrochlorothiazide Tablets, USP, 100 mg/25 mg, a) 30-count bottles (NDC# 33342-052-07), b) 90-count bottles (NDC # 33342-052-10) c) 1000-count bottles (NDC # 33342-052-44), Rx Only, MFR: Macleods Pharma USA, Inc. Plainsboro, NJ 08536 |
| Recalling firm | Macleods Pharma Usa Inc |
| Distribution | Product was distributed nationwide. |
| Quantity | N/A |
| Recall initiated | 2022-04-15 |
| Report date | 2022-05-11 |
| Recall completed | 2023-10-13 |
| Recall number | D-0836-2022 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Plainsboro NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗